Cargando…
The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
A longitudinal molecular model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is lacking. We have recently validated a high fat/sugar water-induced animal (an isogenic strain of C57BL/6 J:129S1/SvImJ mice) model of NAFLD that closely mimics most aspects of h...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722878/ https://www.ncbi.nlm.nih.gov/pubmed/29222421 http://dx.doi.org/10.1038/s41598-017-17370-6 |
_version_ | 1783285095071744000 |
---|---|
author | Cazanave, Sophie Podtelezhnikov, Alexei Jensen, Kristian Seneshaw, Mulugeta Kumar, Divya P. Min, Hae-Ki Santhekadur, Prasanna K. Banini, Bubu Mauro, Adolfo Gabriele M. Oseini, Abdul Vincent, Robert Tanis, Keith Q. Webber, Andrea L. Wang, Liangsu Bedossa, Pierre Mirshahi, Faridoddin Sanyal, Arun J. |
author_facet | Cazanave, Sophie Podtelezhnikov, Alexei Jensen, Kristian Seneshaw, Mulugeta Kumar, Divya P. Min, Hae-Ki Santhekadur, Prasanna K. Banini, Bubu Mauro, Adolfo Gabriele M. Oseini, Abdul Vincent, Robert Tanis, Keith Q. Webber, Andrea L. Wang, Liangsu Bedossa, Pierre Mirshahi, Faridoddin Sanyal, Arun J. |
author_sort | Cazanave, Sophie |
collection | PubMed |
description | A longitudinal molecular model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is lacking. We have recently validated a high fat/sugar water-induced animal (an isogenic strain of C57BL/6 J:129S1/SvImJ mice) model of NAFLD that closely mimics most aspects of human disease. The hepatic transcriptome of such mice with fatty liver (8 weeks), steatohepatitis with early fibrosis (16–24 weeks) and advanced fibrosis (52 weeks) after initiation of the diet was evaluated and compared to mice on chow diet. Fatty liver development was associated with transcriptional activation of lipogenesis, FXR-RXR, PPAR-α mediated lipid oxidation and oxidative stress pathways. With progression to steatohepatitis, metabolic pathway activation persisted with additional activation of IL-1/inhibition of RXR, granulocyte diapedesis/adhesion, Fc macrophage activation, prothrombin activation and hepatic stellate cell activation. Progression to advanced fibrosis was associated with dampening of metabolic, oxidative stress and cell stress related pathway activation but with further Fc macrophage activation, cell death and turnover and activation of cancer-related networks. The molecular progression of NAFLD involves a metabolic perturbation which triggers subsequent cell stress and inflammation driving cell death and turnover. Over time, inflammation and fibrogenic pathways become dominant while in advanced disease an inflammatory-oncogenic profile dominates. |
format | Online Article Text |
id | pubmed-5722878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-57228782017-12-12 The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease Cazanave, Sophie Podtelezhnikov, Alexei Jensen, Kristian Seneshaw, Mulugeta Kumar, Divya P. Min, Hae-Ki Santhekadur, Prasanna K. Banini, Bubu Mauro, Adolfo Gabriele M. Oseini, Abdul Vincent, Robert Tanis, Keith Q. Webber, Andrea L. Wang, Liangsu Bedossa, Pierre Mirshahi, Faridoddin Sanyal, Arun J. Sci Rep Article A longitudinal molecular model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is lacking. We have recently validated a high fat/sugar water-induced animal (an isogenic strain of C57BL/6 J:129S1/SvImJ mice) model of NAFLD that closely mimics most aspects of human disease. The hepatic transcriptome of such mice with fatty liver (8 weeks), steatohepatitis with early fibrosis (16–24 weeks) and advanced fibrosis (52 weeks) after initiation of the diet was evaluated and compared to mice on chow diet. Fatty liver development was associated with transcriptional activation of lipogenesis, FXR-RXR, PPAR-α mediated lipid oxidation and oxidative stress pathways. With progression to steatohepatitis, metabolic pathway activation persisted with additional activation of IL-1/inhibition of RXR, granulocyte diapedesis/adhesion, Fc macrophage activation, prothrombin activation and hepatic stellate cell activation. Progression to advanced fibrosis was associated with dampening of metabolic, oxidative stress and cell stress related pathway activation but with further Fc macrophage activation, cell death and turnover and activation of cancer-related networks. The molecular progression of NAFLD involves a metabolic perturbation which triggers subsequent cell stress and inflammation driving cell death and turnover. Over time, inflammation and fibrogenic pathways become dominant while in advanced disease an inflammatory-oncogenic profile dominates. Nature Publishing Group UK 2017-12-08 /pmc/articles/PMC5722878/ /pubmed/29222421 http://dx.doi.org/10.1038/s41598-017-17370-6 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Cazanave, Sophie Podtelezhnikov, Alexei Jensen, Kristian Seneshaw, Mulugeta Kumar, Divya P. Min, Hae-Ki Santhekadur, Prasanna K. Banini, Bubu Mauro, Adolfo Gabriele M. Oseini, Abdul Vincent, Robert Tanis, Keith Q. Webber, Andrea L. Wang, Liangsu Bedossa, Pierre Mirshahi, Faridoddin Sanyal, Arun J. The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease |
title | The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease |
title_full | The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease |
title_fullStr | The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease |
title_full_unstemmed | The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease |
title_short | The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease |
title_sort | transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722878/ https://www.ncbi.nlm.nih.gov/pubmed/29222421 http://dx.doi.org/10.1038/s41598-017-17370-6 |
work_keys_str_mv | AT cazanavesophie thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT podtelezhnikovalexei thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT jensenkristian thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT seneshawmulugeta thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT kumardivyap thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT minhaeki thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT santhekadurprasannak thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT baninibubu thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT mauroadolfogabriele thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT moseiniabdul thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT vincentrobert thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT taniskeithq thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT webberandreal thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT wangliangsu thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT bedossapierre thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT mirshahifaridoddin thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT sanyalarunj thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT cazanavesophie transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT podtelezhnikovalexei transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT jensenkristian transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT seneshawmulugeta transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT kumardivyap transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT minhaeki transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT santhekadurprasannak transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT baninibubu transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT mauroadolfogabriele transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT moseiniabdul transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT vincentrobert transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT taniskeithq transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT webberandreal transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT wangliangsu transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT bedossapierre transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT mirshahifaridoddin transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease AT sanyalarunj transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease |